Vivos Therapeutics (VVOS) Common Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Common Equity data on file, last reported at -$1.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$1.3 million, down 128.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 128.75% YoY), and the FY2025 annual result was -$1.5 million, down 119.49% from the prior year.
• Common Equity advanced to -$1.3 million in Q1 2026 per VVOS's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Common Equity peaked at $21.0 million in Q1 2022 and troughed at -$1.5 million in Q4 2025.
• A 5-year average of $5.4 million and a median of $4.6 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2026: Common Equity soared 16563.04% in 2024, then sank 128.75% in 2026.
• A 5-year view of Common Equity shows it stood at $4.8 million in 2022, then plunged by 91.44% to $411000.0 in 2023, then soared by 1835.28% to $8.0 million in 2024, then sank by 119.49% to -$1.5 million in 2025, then advanced by 18.26% to -$1.3 million in 2026.
• Business Quant data shows VVOS's Common Equity at -$1.3 million in Q1 2026, -$1.5 million in Q4 2025, and $2.5 million in Q3 2025.